BARICITINIB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H17N7O2S
Molecular Weight	371.417
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of BARICITINIB

Structure Search

SMILES

CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

InChI

InChIKey=XUZMWHLSFXCVMG-UHFFFAOYSA-N

InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)

HIDE SMILES / InChI

Molecular Formula	C16H17N7O2S
Molecular Weight	371.417
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:30:36 UTC 2023` Edited by `admin` on `Sat Dec 16 01:30:36 UTC 2023`
Record UNII	ISP4442I3Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BARICITINIB

Official Name

English

baricitinib [INN]

Common Name

English

BARICITINIB [ORANGE BOOK]

Common Name

English

LY3009104

Code

English

BARICITINIB [USAN]

Common Name

English

3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-(4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-

Systematic Name

English

BARICITINIB [JAN]

Common Name

English

BARICITINIB [EMA EPAR]

Common Name

English

BARICITINIB [MI]

Common Name

English

INCB028050

Code

English

Baricitinib [WHO-DD]

Common Name

English

INCB-028050

Code

English

LY-3009104

Code

English

OLUMIANT

Brand Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

OLUMIANT (AUTHORIZED: ARTHRITIS, RHEUMATOID)

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

NCI_THESAURUS

C1967

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

FDA ORPHAN DRUG

610017

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

NCI_THESAURUS

C129825

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

WHO-ATC

L04AA37

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

NDF-RT

N0000190858

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

Code System Code Type Description

DAILYMED

ISP4442I3Y

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

SMS_ID

100000166701

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

WIKIPEDIA

Baricitinib

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

PUBCHEM

44205240

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

FDA UNII

ISP4442I3Y

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

USAN

YY-82

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

DRUG BANK

DB11817

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

DRUG CENTRAL

5202

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

NCI_THESAURUS

C127012

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

EVMPD

SUB180983

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

ChEMBL

CHEMBL2105759

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

CAS

1187594-09-7

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

MERCK INDEX

m12076

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

RXCUI

2047232

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

LACTMED

Baricitinib

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

INN

9570

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

EPA CompTox

DTXSID30152228

Created by admin on Sat Dec 16 01:30:36 UTC 2023 , Edited by admin on Sat Dec 16 01:30:36 UTC 2023

PRIMARY

Related Record Type Details


					ISP4442I3Y

EXCRETED UNCHANGED

Qualification:

URINE

Amount:


					9LLR266790

TYROSINE-PROTEIN KINASE JAK3

TARGET->WEAK INHIBITOR


					XIB47S8NNB

BARICITINIB PHOSPHATE

SALT/SOLVATE -> PARENT


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE

Comments:

Only 4 minor oxidative metabolites were identified (3 in urine; 1 in faeces) constituting approximately 5 % and 1 % of the dose, respectively.


					76UB6O122H

ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2

TRANSPORTER -> SUBSTRATE

Comments:

Coadministration of baricitinib with ciclosporin (Pgp/BCRP inhibitor) resulted in no clinically meaningful effects on baricitinib exposure.


					GL209F9TZS

TYROSINE-PROTEIN KINASE JAK2

TARGET -> INHIBITOR


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE

Comments:

Coadministration of baricitinib with ciclosporin (Pgp/BCRP inhibitor) resulted in no clinically meaningful effects on baricitinib exposure.


					ISP4442I3Y

EXCRETED UNCHANGED

Qualification:

FECAL

Amount:


					ZWJ2Y6JZWY

OAT-3

TRANSPORTER -> SUBSTRATE

Comments:

A clinical pharmacology study, dosing of probenecid (an OAT3 inhibitor with strong inhibition potential) resulted in approximately a 2-fold increase in AUC(0-∞) with no change in tmax or Cmax of baricitinib.


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					08S4A2S6FT

TYROSINE-PROTEIN KINASE JAK1

TARGET -> INHIBITOR

Qualification:

IC50

Amount:

Related Record Type Details


					J63UPD4QSA

4-AMINO-6-(1-(3-(CYANOMETHYL)-1-ETHYLSULFONYL-AZETIDIN-3-YL)PYRAZOL-4-YL)PYRIMIDINE-5-CARBOXYLIC ACID

METABOLITE -> PARENT


					PC4Y9UB4UF

2-(4-AMINO-6-(1-(3-(CYANOMETHYL)-1-(ETHYLSULFONYL)AZETIDIN-3-YL)-1H-PYRAZOL-4-YL)PYRIMIDIN-5-YL)ACETIC ACID

METABOLITE -> PARENT

Related Record Type Details


					ISP4442I3Y

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Volume of Distribution	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC